Renaissance Technologies LLC Purchases 84,350 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Renaissance Technologies LLC grew its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 158.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 137,500 shares of the biotechnology company's stock after purchasing an additional 84,350 shares during the period. Renaissance Technologies LLC owned approximately 0.43% of Capricor Therapeutics worth $656,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. BNP Paribas Financial Markets bought a new stake in shares of Capricor Therapeutics during the 1st quarter valued at approximately $40,000. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock worth $9,274,000 after buying an additional 200,499 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock valued at $381,000 after acquiring an additional 9,040 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics during the 2nd quarter valued at $147,000. Finally, Main Street Financial Solutions LLC grew its position in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after acquiring an additional 7,500 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

Insiders Place Their Bets

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The stock was bought at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now directly owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 12.00% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Maxim Group increased their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Oppenheimer reissued an "outperform" rating and set a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. Cantor Fitzgerald restated an "overweight" rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a report on Friday, September 20th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $22.60.

Capricor Therapeutics Trading Down 10.5 %

CAPR stock traded down $2.02 during midday trading on Wednesday, hitting $17.31. The stock had a trading volume of 3,584,406 shares, compared to its average volume of 1,053,014. The firm has a market cap of $553.56 million, a P/E ratio of -20.26 and a beta of 4.01. The business has a fifty day moving average price of $6.63 and a two-hundred day moving average price of $5.84. Capricor Therapeutics Inc has a 1-year low of $2.68 and a 1-year high of $21.98.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. On average, equities analysts anticipate that Capricor Therapeutics Inc will post -1.14 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.